Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) for the period ending August 21, 2015. The report details a new material definitive agreement and significant updates regarding ongoing litigation matters.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed is a court-ordered award of attorney's fees and costs in the amount of $770,852 to be paid to the Company by a former investment bank.
Material Changes and Events
- Supply Agreement: On August 21, 2015, the Company executed an agreement with Gulf Coast Regional Blood Center (effective July 1, 2015) to supply leukocyte concentrates required for the manufacture of Alferon.
- Litigation Victory: The U.S. Court of Appeals for the Third Circuit unanimously upheld the Company's defense against a lawsuit brought by Cato Capital, affirming a September 2014 trial court judgment. The Company was awarded $770,852 in attorney's fees and costs.
- Derivative Suit Update: The Court of Chancery of the State of Delaware denied the Company's motion to dismiss a stockholder derivative complaint filed in June 2013 alleging breaches of fiduciary duties. The Company anticipates filing an answer shortly to commence discovery.
Outlook, Risks, and Contingencies
The Company intends to pursue the collection of the $770,852 award from Cato Capital to the fullest extent of the law. Regarding the stockholder derivative suit, the denial of the motion to dismiss indicates the litigation will proceed to the discovery phase, representing a continuing legal contingency and potential cost.
Investor Verification Checklist
- Verify the operational impact of the new supply agreement with Gulf Coast Regional Blood Center on Alferon production.
- Confirm the status of collection efforts for the $770,852 legal award from Cato Capital.
- Monitor the progress of the stockholder derivative suit (Rena A. Kastis and James E. Conroy v. Hemispherx Biopharma, Inc.) following the denial of the dismissal motion.
- Note the discrepancy between the requested company name (AIM Immunotech Inc.) and the actual registrant (Hemispherx Biopharma, Inc.).